Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-03-13
DOI
10.3389/fphar.2019.00212
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Review article: novel oral-targeted therapies in inflammatory bowel disease
- (2018) J. R. White et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults
- (2018) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease
- (2018) Amy Hemperly et al. INFLAMMATORY BOWEL DISEASES
- Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
- (2018) Uma Mahadevan et al. INFLAMMATORY BOWEL DISEASES
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
- (2018) Bruce E Sands et al. Journal of Crohns & Colitis
- Amelioration of colitis through blocking lymphocytes entry to Peyer's patches by sphingosine-1-phosphate lyase inhibitor
- (2018) Kazuhiko Shirakabe et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
- (2018) Wagner Ricardo Montor et al. Molecular Cancer
- Progressive multifocal leukoencephalopathy after fingolimod treatment
- (2018) Joseph R. Berger et al. NEUROLOGY
- The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
- (2018) Andrea Huwiler et al. PHARMACOLOGY & THERAPEUTICS
- Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis
- (2018) Eun Ha Kang et al. Current Rheumatology Reports
- Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts
- (2018) Tamara Pérez-Jeldres et al. INFLAMMATORY BOWEL DISEASES
- Targeting JAK-STAT signal transduction in IBD
- (2018) Christoffer Soendergaard et al. PHARMACOLOGY & THERAPEUTICS
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
- (2018) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- New treatment strategies for ulcerative colitis
- (2017) Julian Panés et al. Expert Review of Clinical Immunology
- JAK inhibition in inflammatory bowel disease
- (2017) Pablo Olivera et al. Expert Review of Clinical Immunology
- Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest
- (2017) William J. Sandborn et al. GASTROENTEROLOGY
- Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease
- (2017) Brigid S. Boland et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- A Case Series on Patients on Tofacitinib in Combination With a Biologic
- (2017) Nashla S. Barroso et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
- (2017) Frédéric Vanhoutte et al. Arthritis & Rheumatology
- Frontiers in Drug Research and Development for Inflammatory Bowel Disease
- (2017) Diego Currò et al. Frontiers in Pharmacology
- Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis
- (2017) Hui Zhang et al. CIRCULATION
- Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
- (2016) F L Scott et al. BRITISH JOURNAL OF PHARMACOLOGY
- Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans
- (2016) Wei-Ching Huang et al. FASEB JOURNAL
- Next generation of small molecules in inflammatory bowel disease
- (2016) Pablo Olivera et al. GUT
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
- (2016) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Altered STAT4 Isoform Expression in Patients with Inflammatory Bowel Disease
- (2015) Rukhsana Jabeen et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases
- (2015) Andres J. Yarur et al. INFLAMMATORY BOWEL DISEASES
- Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
- (2015) Lauren L. Levy et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Small molecule drugs with immunomodulatory effects in cancer
- (2015) Adrian G Murphy et al. Human Vaccines & Immunotherapeutics
- Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
- (2015) Christina Charles-Schoeman et al. Arthritis & Rheumatology
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs
- (2014) Emilie Degagné et al. JOURNAL OF CLINICAL INVESTIGATION
- Mechanisms of Jak/STAT Signaling in Immunity and Disease
- (2014) Alejandro V. Villarino et al. JOURNAL OF IMMUNOLOGY
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibiting Janus kinases to treat alopecia areata
- (2014) Sherrie J Divito et al. NATURE MEDICINE
- Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
- (2014) Thorsten Hornung et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
- (2014) Leeyen Hsu et al. Journal of Immunology Research
- S1P1localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity
- (2013) David C. Montrose et al. JOURNAL OF LIPID RESEARCH
- Therapeutic modulators of STAT signalling for human diseases
- (2013) Gabriella Miklossy et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
- (2012) I Ordás et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Fingolimod for Multiple Sclerosis
- (2012) Daniel Pelletier et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacologic Evaluation of Sulfasalazine, FTY720, and Anti-IL-12/23p40 in a TNBS-Induced Crohn’s Disease Model
- (2011) Zaher A. Radi et al. DIGESTIVE DISEASES AND SCIENCES
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
- (2010) Asher Kornbluth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The transcription factors STAT5A/B regulate GM-CSF-mediated granulopoiesis
- (2009) A. Kimura et al. BLOOD
- Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases
- (2009) Xiaoyu Hu et al. IMMUNITY
- Inflammatory Bowel Disease
- (2009) Clara Abraham et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effects of IL-6 on CD4 T cell responses
- (2008) Oliver Dienz et al. CLINICAL IMMUNOLOGY
- FTY720 (fingolimod) for relapsing multiple sclerosis
- (2008) Alejandro Horga et al. Expert Review of Neurotherapeutics
- A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis
- (2008) Ashley J. Snider et al. FASEB JOURNAL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started